Brachytherapy · 2025
Dosimetric comparison between I-125 seed implantation and stereotactic body radiotherapy (SBRT) in patients with hepatic malignancies.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Xu, Zhang Bo, Kong Qi, Li Yuheng, Fan Pengfei, Wu Dengbin
Аннотация
PURPOSE: This study aims to compare the dosimetric values of I-125 seed implantation with stereotactic body radiotherapy (SBRT) in the treatment of hepatic cancer patients.
METHODS AND MATERIALS: The study retrospectively analyzed 23 patients with hepatic malignancies treated with SBRT. A virtual I-125 seed implantation plan was simulated for comparison. For I-125 seed implantation, a prescription dose of 110 Gy was delivered to the gross tumor volume (GTV), corresponding to the planned target volume (PTV) in SBRT. Dosimetric values, including target coverage and dose to organs at risk (OARs), were compared using paired t-tests.
RESULTS AND CONCLUSIONS: The average PTV volume receiving 100% of the prescription dose was similar between the I-125 and SBRT groups (86.0% vs. 78.7%, p = 0.172). The I-125 group mean PTV V150% 62.9% ± 8.5%, while SBRT plans inherently restrict maximum PTV doses to ≤150% (resulting in 0% V150%). The mean minimum dose to PTV was significantly greater in the I-125 group than in the SBRT group (5562.49 cGy vs. 3289.69 cGy, p < 0.01). Regarding OARs, the liver volume receiving ≥15 Gy was significantly lower in the I-125 group (274.67 cc vs. 485.72 cc, p < 0.01), with similar trends observed for the small intestine, kidneys, stomach, and colon. Dosimetric analysis revealed differences in dose distribution within the target volume and efficient OARs sparing using I-125 seed implantation compared with SBRT. Additional studies are required to examine the clinical relevance of these findings and determine whether combining these two methods may offer higher therapeutic benefit.
METHODS AND MATERIALS: The study retrospectively analyzed 23 patients with hepatic malignancies treated with SBRT. A virtual I-125 seed implantation plan was simulated for comparison. For I-125 seed implantation, a prescription dose of 110 Gy was delivered to the gross tumor volume (GTV), corresponding to the planned target volume (PTV) in SBRT. Dosimetric values, including target coverage and dose to organs at risk (OARs), were compared using paired t-tests.
RESULTS AND CONCLUSIONS: The average PTV volume receiving 100% of the prescription dose was similar between the I-125 and SBRT groups (86.0% vs. 78.7%, p = 0.172). The I-125 group mean PTV V150% 62.9% ± 8.5%, while SBRT plans inherently restrict maximum PTV doses to ≤150% (resulting in 0% V150%). The mean minimum dose to PTV was significantly greater in the I-125 group than in the SBRT group (5562.49 cGy vs. 3289.69 cGy, p < 0.01). Regarding OARs, the liver volume receiving ≥15 Gy was significantly lower in the I-125 group (274.67 cc vs. 485.72 cc, p < 0.01), with similar trends observed for the small intestine, kidneys, stomach, and colon. Dosimetric analysis revealed differences in dose distribution within the target volume and efficient OARs sparing using I-125 seed implantation compared with SBRT. Additional studies are required to examine the clinical relevance of these findings and determine whether combining these two methods may offer higher therapeutic benefit.